{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T08:12:09Z","timestamp":1794989529493,"version":"4.9.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Independent Research and Development Program"},{"name":"Veterans Health Administration"},{"DOI":"10.13039\/100031313","name":"Herbert Irving Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031313","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Blavatnik Foundation"},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pancreas Center"},{"DOI":"10.13039\/100001784","name":"Pancreatic Cancer Action Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We applied 11 mathematical models of tumor growth to clinical trial data available from public and private sources. We have previously described the remarkable capacity for a simple biexponential model to describe the kinetics of tumor growth, fit thousands of datasets, and correlate with overall survival. We sought to extend our analysis to additional tumor types and to evaluate whether alternate growth models could describe the time course of disease burden in the small subset of patients in whom the biexponential model failed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Data were available from 17 140 patients including imaging data for 3346 patients and serum levels of tumor markers for 13 794 patients. Data from patients were analyzed using the biexponential model to determine rates of tumor growth (g) and regression (d); for those whose data could not be described by this model, fit of their data was assessed using seven alternative models. The rates of tumor growth (g rate), a continuous variable, were examined for association with the gold-standard of clinical trials, overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>As we have previously reported, data from most patients fit a simple model of exponential growth and exponential regression (86%). Data from another 7% of patients fit an alternative model. We found growth rate correlates inversely with overall survival, remarkably even when data from various histologies are considered together. For patients with multiple timepoints of tumor measurement, growth rate could often be estimated even during the phase when only net regression could be discerned.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Validation of a simple mathematical model across different cancers and its application to existing clinical data allowed estimation of the rate of growth of a treatment resistant subpopulation of cancer cells. The quantification of available clinical data using the growth rate of tumors in individual patients and its strong correlation with overall survival makes the growth rate an excellent marker of the efficacy of therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf353","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T11:42:36Z","timestamp":1760787756000},"source":"Crossref","is-referenced-by-count":3,"title":["Cancer interception during treatment: using growth kinetics to create a continuous variable for assessing disease response"],"prefix":"10.1093","volume":"30","author":[{"given":"Mengxi","family":"Zhou","sequence":"first","affiliation":[{"name":"Columbia University Medical Center Department of Medicine, Division of Hematology\/Oncology, , New York, NY 10032,","place":["USA"]},{"name":"James J Peters VA Medical Centre , Bronx , New York, NY 10032,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio T","family":"Fojo","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center Department of Medicine, Division of Hematology\/Oncology, , New York, NY 10032,","place":["USA"]},{"name":"James J Peters VA Medical Centre , Bronx , New York, NY 10032,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center Department of Radiology, , New York, NY, 10065,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6708-0330","authenticated-orcid":false,"given":"Susan E","family":"Bates","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center Department of Medicine, Division of Hematology\/Oncology, , New York, NY 10032,","place":["USA"]},{"name":"James J Peters VA Medical Centre , Bronx , New York, NY 10032,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7438-0478","authenticated-orcid":false,"given":"Krastan B","family":"Blagoev","sequence":"additional","affiliation":[{"name":"National Science Foundation , Alexandria, VA 22230,","place":["USA"]},{"name":"Department of Biophysics, Johns Hopkins University , Baltimore, MD 21218,","place":["USA"]},{"name":"Institute of Molecular Biology, Bulgarian Academy of Sciences , Sofia 1113,","place":["Bulgaria"]},{"name":"Institut Curie, PSL Research University, Sorbonne Universit\u00e9, CNRS UMR3664, Laboratoire Dynamique du Noyau , 75005 Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"2025111620341624300_oyaf353-B1","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1158\/1078-0432.CCR-11-2275","article-title":"Analyzing the pivotal trial that compared sunitinib and IFN-\u03b1 in renal cell carcinoma, using a method that assesses tumor regression and growth","volume":"18","author":"Stein","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025111620341624300_oyaf353-B2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.celrep.2013.01.015","article-title":"Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma","volume":"3","author":"Blagoev","year":"2013","journal-title":"Cell Rep"},{"key":"2025111620341624300_oyaf353-B3","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1158\/0008-5472.CAN-14-0420","article-title":"Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers","volume":"74","author":"Blagoev","year":"2014","journal-title":"Cancer Res"},{"key":"2025111620341624300_oyaf353-B4","doi-asserted-by":"publisher","first-page":"e96316","DOI":"10.1371\/journal.pone.0096316","article-title":"Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example","volume":"9","author":"Burotto","year":"2014","journal-title":"PLoS One"},{"key":"2025111620341624300_oyaf353-B5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(16)30633-7","article-title":"Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis","volume":"18","author":"Wilkerson","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025111620341624300_oyaf353-B6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1053\/j.seminoncol.2019.11.004","article-title":"A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on veterans treated with abiraterone and enzalutamide","volume":"46","author":"Leuva","year":"2019","journal-title":"Semin Oncol"},{"key":"2025111620341624300_oyaf353-B7","doi-asserted-by":"publisher","first-page":"6464","DOI":"10.1158\/1078-0432.CCR-20-1493","article-title":"Enhanced detection of treatment effects on metastatic colorectal cancer with volumetric CT measurements for tumor burden growth rate evaluation","volume":"26","author":"Maitland","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025111620341624300_oyaf353-B8","doi-asserted-by":"publisher","first-page":"e632","DOI":"10.1002\/onco.13669","article-title":"Novel tumor growth rate analysis in the randomized CLARINET study establishes the efficacy of lanreotide depot\/autogel 120 mg with prolonged administration in indolent neuroendocrine tumors","volume":"26","author":"Dromain","year":"2021","journal-title":"Oncologist"},{"key":"2025111620341624300_oyaf353-B9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1053\/j.seminoncol.2021.02.001","article-title":"Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: comparative effectiveness and evaluation of tumor growth in veterans","volume":"48","author":"Siegel","year":"2021","journal-title":"Semin Oncol"},{"key":"2025111620341624300_oyaf353-B10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/oncolo\/oyac217","article-title":"Tumor growth rate informs treatment efficacy in metastatic pancreatic adenocarcinoma: application of a growth and regression model to pivotal trial and real-world data","volume":"28","author":"Yeh","year":"2023","journal-title":"Oncologist"},{"key":"2025111620341624300_oyaf353-B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-023-07131-7","article-title":"Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials","volume":"204","author":"Yeh","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"2025111620341624300_oyaf353-B12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nrgastro.2012.115","article-title":"The role of stroma in pancreatic cancer: diagnostic and therapeutic implications","volume":"9","author":"Erkan","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025111620341624300_oyaf353-B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.18632\/oncotarget.27855","article-title":"Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer","volume":"12","author":"Blagoev","year":"2021","journal-title":"Oncotarget"},{"key":"2025111620341624300_oyaf353-B14","doi-asserted-by":"publisher","first-page":"105288","DOI":"10.1016\/j.ediom.2024.105288","article-title":"Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analyses","volume":"107","author":"Leuva","year":"2024","journal-title":"EBioMedicine"},{"key":"2025111620341624300_oyaf353-B15","doi-asserted-by":"publisher","first-page":"187ps9","DOI":"10.1126\/scitranslmed.3005686","article-title":"Clinically relevant modeling of tumor growth and treatment response","volume":"5","author":"Yankeelov","year":"2013","journal-title":"Sci Transl Med"},{"key":"2025111620341624300_oyaf353-B16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/psp4.12145","article-title":"Time-dependent bias of tumor growth rate and time to tumor regrowth","volume":"5","author":"Mistry","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025111620341624300_oyaf353-B17","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/cpt.986","article-title":"Population modeling of tumor kinetics and overall survival to identify prognostic and predictive biomarkers of efficacy for durvalumab in patients with urothelial carcinoma","volume":"103","author":"Zheng","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2025111620341624300_oyaf353-B18","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1158\/1078-0432.CCR-17-3662","article-title":"A model of overall survival predicts treatment outcomes with atezolizumab versus chemotherapy in non-small cell lung cancer based on early tumor kinetics","volume":"24","author":"Claret","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025111620341624300_oyaf353-B19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1186\/s12885-019-5911-y","article-title":"Best fitting tumor growth models of the von Bertalanffy-P\u00fctterType","volume":"19","author":"K\u00fchleitner","year":"2019","journal-title":"BMC Cancer"},{"key":"2025111620341624300_oyaf353-B20","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/cpt.1450","article-title":"Association between tumor size kinetics and survival in patients with urothelial carcinoma treated with atezolizumab: implication for patient follow-up","volume":"106","author":"Tardivon","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2025111620341624300_oyaf353-B21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/psp4.12542","article-title":"Tumor growth dynamic modeling in oncology drug development and regulatory approval: past, present, and future opportunities","volume":"9","author":"Al-Huniti","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025111620341624300_oyaf353-B22","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/psp4.12686","article-title":"Prediction of overall survival in patients across solid tumors following atezolizumab treatments: a tumor growth inhibition-overall survival modeling framework","volume":"10","author":"Chan","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025111620341624300_oyaf353-B23","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/1078-0432.CCR-22-2323","article-title":"Tumor dynamic model-based decision support for phase Ib\/II combination studies: a retrospective assessment based on resampling of the phase III study IMpower150","volume":"29","author":"Bruno","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025111620341624300_oyaf353-B24","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/cpt.3371","article-title":"Predicting survival in patients with advanced NSCLC treated with atezolizumab using pre- and on-treatment prognostic biomarkers","volume":"116","author":"Benzekry","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"2025111620341624300_oyaf353-B25","doi-asserted-by":"publisher","first-page":"1470555","DOI":"10.3389\/fimmu.2024.1470555","article-title":"Assessing immunotherapy response: going beyond RECIST by integrating early tumor growth kinetics","volume":"15","author":"Felfli","year":"2024","journal-title":"Front Immunol"},{"key":"2025111620341624300_oyaf353-B26","doi-asserted-by":"publisher","first-page":"oyaf057","DOI":"10.1093\/oncolo\/oyaf05","article-title":"Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan","volume":"30","author":"He","year":"2025","journal-title":"Oncologist"},{"key":"2025111620341624300_oyaf353-B27","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1083\/jcb.201807037","article-title":"Emerging mechanisms of asymmetric stem cell division","volume":"217","author":"Venkei","year":"2018","journal-title":"J Cell Biol"},{"key":"2025111620341624300_oyaf353-B28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13619-024-00188-9","article-title":"Asymmetric division of stem cells and its cancer relevance","volume":"13","author":"Chao","year":"2024","journal-title":"Cell Regen"},{"key":"2025111620341624300_oyaf353-B29","doi-asserted-by":"publisher","first-page":"13932","DOI":"10.1038\/s41598-025-97985-2","article-title":"Asymmetric cell division of ALDH1-positive cancer stem cells generates glycolytic metabolically diverse cell populations","volume":"15","author":"Tamori","year":"2025","journal-title":"Sci Rep"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf353\/64857561\/oyaf353.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf353\/64857561\/oyaf353.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf353\/64857561\/oyaf353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T01:34:22Z","timestamp":1763343262000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf353\/8297111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf353","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,22]]},"article-number":"oyaf353"}}